{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-096313","form_type":"8-K","ticker":"STRO","cik":"0001382101","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2024-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.847315+00:00","generated_at":"2026-05-31T09:38:55.020555+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Sutro reports Q2 revenue $25.7M, cash $426M; luvelta trials advancing","bullets":["Revenue $25.7M (up from $10.4M YoY) driven by Astellas collaboration and Vaxcyte agreement.","Cash, equivalents, and securities $375.6M; Vaxcyte stock fair value $50.4M (total $426M).","Operating expenses $74.4M (R&D $62.0M, G&A $12.4M); includes non-cash stock comp and depreciation.","Luvelta Phase 3 REFRαME-O1 randomized portion underway; pediatric AML trial (REFRαME-P1) expected H2 2024.","Appointed Sukhi Jagpal to Board and Barbara Leyman as Chief Business Development Officer."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-096313","json":"https://secwatch.observer/filing/0000950170-24-096313.json","markdown":"https://secwatch.observer/filing/0000950170-24-096313.md","text":"https://secwatch.observer/filing/0000950170-24-096313.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1382101/000095017024096313/0000950170-24-096313-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1382101/000095017024096313/stro-20240813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:38:55.020555+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}